Soyoon Park
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Soyoon Park has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
- Abigail E. Powell
Vir Biotechnology, San Francisco, CA 94158, USA
4 shared publications - Daniel J. Stieh
Vaccine Company, Inc., South San Francisco, CA, USA
3 shared publications Hannah Caruso
Vaccine Company Inc., South San Francisco, USA
3 shared publicationsJulie E. Ledgerwood
Vaccine Company, Inc., South San Francisco, CA, USA
3 shared publicationsAnneliese Bruening
Department of Biomedical Sciences, Colorado State University, Fort Collins, CO, USA
2 shared publicationsBrad A. Palanski
Vaccine Company, Inc., South San Francisco, CA, USA
2 shared publications
Latest Publications
- Open Access
Antibody design across observed and forecasted antigenic evolution
The therapeutic efficacy of antibodies is often limited by the evolution of their targets. Designing or eliciting antibodies that withstand such evolution is challenging as their binding interfaces must accommodate antigenic variation. Here, we introduce Germinal Multi, a computational framework for de novo antibody design and rescue that jointly optimizes a single paratope against multiple antigenic variants. We applied Germinal Multi to cancer and viral antigens, targeting both observed antigenic variation and prospective antibody escape. Multi-target optimization yielded antibodies that bound resistance-associated EGFR variants or that neutralized antigenically distinct historical SARS-CoV-2 variants, with recognition extending to variants withheld from the design process. Beyond acting on observed evolution, we redesigned the broadly neutralizing antibody BD55-1205 to restore neutralization of a prospective escape variant engineered with guidance from an evolutionary forecasting model, while preserving activity against the parental variant. Successful candidates were identified after screening tens of designs per campaign. Together, these results establish multi-target computational design as a strategy for generating antibody breadth across observed antigenic variation and demonstrate the potential of evolutionary forecasting to guide antibody redesign against prospective escape.
Open AccessAntibody design across observed and forecasted antigenic evolution
The therapeutic efficacy of antibodies is often limited by the evolution of their targets. Designing or eliciting antibodies that withstand such evolution is challenging as their binding interfaces must accommodate antigenic variation. Here, we introduce Germinal Multi, a computational framework for de novo antibody design and rescue that jointly optimizes a single paratope against multiple antigenic variants. We applied Germinal Multi to cancer and viral antigens, targeting both observed antigenic variation and prospective antibody escape. Multi-target optimization yielded antibodies that bound resistance-associated EGFR variants or that neutralized antigenically distinct historical SARS-CoV-2 variants, with recognition extending to variants withheld from the design process. Beyond acting on observed evolution, we redesigned the broadly neutralizing antibody BD55-1205 to restore neutralization of a prospective escape variant engineered with guidance from an evolutionary forecasting model, while preserving activity against the parental variant. Successful candidates were identified after screening tens of designs per campaign. Together, these results establish multi-target computational design as a strategy for generating antibody breadth across observed antigenic variation and demonstrate the potential of evolutionary forecasting to guide antibody redesign against prospective escape.
- Open Access
Forecasting viral antigenic evolution from phylogenetic trees
Forecasting the evolution of viral proteins can help inform pandemic preparedness and guide the development of interventions. Phylogenetic trees provide historical records of pathogen evolution, which are key for retrospective analysis, but using them to predict future genotypic changes remains challenging. We introduce antiGen, a machine learning model that learns from the evolutionary past of viruses to forecast the evolutionary future. antiGen achieves state-of-the-art performance in forecasting SARS-CoV-2 spike protein mutations according to a variety of metrics, including the prediction of mutations in the receptor binding domain, mutations never previously seen, and mutations with high prevalence. Most experimentally tested antiGen-forecasted spike variants retain pseudoviral infectivity in vitro, supporting their functional plausibility. Evaluations on surface proteins of influenza virus, respiratory syncytial virus, and dengue virus further demonstrate applicability across viruses with differing amounts of available sequencing data. Finally, we develop a model trained across 49 viral proteins from 27 viruses, which improves forecasting performance over models trained on individual protein phylogenies. Together, these results support learning from phylogenetic histories as an approach to model viral amino acid changes prospectively, with applications in epidemiology and therapeutic development.
Open AccessForecasting viral antigenic evolution from phylogenetic trees
Forecasting the evolution of viral proteins can help inform pandemic preparedness and guide the development of interventions. Phylogenetic trees provide historical records of pathogen evolution, which are key for retrospective analysis, but using them to predict future genotypic changes remains challenging. We introduce antiGen, a machine learning model that learns from the evolutionary past of viruses to forecast the evolutionary future. antiGen achieves state-of-the-art performance in forecasting SARS-CoV-2 spike protein mutations according to a variety of metrics, including the prediction of mutations in the receptor binding domain, mutations never previously seen, and mutations with high prevalence. Most experimentally tested antiGen-forecasted spike variants retain pseudoviral infectivity in vitro, supporting their functional plausibility. Evaluations on surface proteins of influenza virus, respiratory syncytial virus, and dengue virus further demonstrate applicability across viruses with differing amounts of available sequencing data. Finally, we develop a model trained across 49 viral proteins from 27 viruses, which improves forecasting performance over models trained on individual protein phylogenies. Together, these results support learning from phylogenetic histories as an approach to model viral amino acid changes prospectively, with applications in epidemiology and therapeutic development.
- Open Access
- 5 February 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
A stabilized MERS-CoV spike ferritin nanoparticle vaccine elicits robust and protective neutralizing antibody responses
Middle East respiratory syndrome coronavirus (MERS-CoV) was identified as a human pathogen in 2012 and causes ongoing sporadic infections and outbreak clusters. Despite case fatality rates (CFRs) of over 30% and considerable pandemic potential, a safe and efficacious vaccine has not been developed. Here we report the design, characterization, and preclinical evaluation of MERS-CoV antigens. Our lead candidate comprises a stabilized spike displayed on a self-assembling ferritin nanoparticle that can be produced from a high-expressing, stable cell pool. This vaccine elicits robust MERS-CoV pseudovirus and authentic virus neutralizing antibody titers in BALB/c mice. Immunization of male non-human primates (NHPs) with one dose of Alhydrogel-adjuvanted vaccine elicited a > 10 3 geometric mean titer of pseudovirus neutralizing antibodies that was boosted with a second dose. Sera from these NHPs exhibited cross-reactivity against spike-pseudotyped lentiviruses from MERS-CoV clades A, B, and C as well as a distant pangolin merbecovirus. In human DPP4 transgenic mice, immunization provided dose-dependent protection against MERS-CoV lethal challenge, and in an established alpaca challenge model using female alpacas, immunization fully protected against MERS-CoV infection. This MERS-CoV nanoparticle vaccine is a promising candidate for clinical advancement to protect at-risk individuals and for future use in a potential outbreak setting.
- 5 February 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessA stabilized MERS-CoV spike ferritin nanoparticle vaccine elicits robust and protective neutralizing antibody responses
Middle East respiratory syndrome coronavirus (MERS-CoV) was identified as a human pathogen in 2012 and causes ongoing sporadic infections and outbreak clusters. Despite case fatality rates (CFRs) of over 30% and considerable pandemic potential, a safe and efficacious vaccine has not been developed. Here we report the design, characterization, and preclinical evaluation of MERS-CoV antigens. Our lead candidate comprises a stabilized spike displayed on a self-assembling ferritin nanoparticle that can be produced from a high-expressing, stable cell pool. This vaccine elicits robust MERS-CoV pseudovirus and authentic virus neutralizing antibody titers in BALB/c mice. Immunization of male non-human primates (NHPs) with one dose of Alhydrogel-adjuvanted vaccine elicited a > 10 3 geometric mean titer of pseudovirus neutralizing antibodies that was boosted with a second dose. Sera from these NHPs exhibited cross-reactivity against spike-pseudotyped lentiviruses from MERS-CoV clades A, B, and C as well as a distant pangolin merbecovirus. In human DPP4 transgenic mice, immunization provided dose-dependent protection against MERS-CoV lethal challenge, and in an established alpaca challenge model using female alpacas, immunization fully protected against MERS-CoV infection. This MERS-CoV nanoparticle vaccine is a promising candidate for clinical advancement to protect at-risk individuals and for future use in a potential outbreak setting.
- Top Cited PapersOpen Access
- 3 January 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Structure and immunogenicity of an engineered soluble prefusion-stabilized EBV gB antigen
Epstein-Barr virus (EBV), the causative agent of mononucleosis, is linked to over 140,000 annual cancer-related deaths globally and increases the risk of multiple sclerosis by up to 32-fold. As a herpesvirus, EBV establishes lifelong infection, and over 90% of U.S. adults are EBV-seropositive. Despite its significant disease burden, no approved EBV vaccines or therapeutics exist. Among EBV envelope glycoproteins, the fusion protein (gB) is strictly required for epithelial and B cell infection. Here, using a combination of AlphaFold-guided modeling, rational design, and ThermoMPNN-informed optimization, we engineer a stabilized prefusion gB variant, C3-GT. This construct incorporates two inter-protomeric disulfide bonds and three cavity-filling substitutions, resulting in a melting temperature of 54 °C. Cryo-EM analysis of this construct reveals the prefusion structure of EBV gB, providing insights into the structural transitions required to adopt the postfusion conformation. Murine immunizations and depletion studies with human sera suggest a trend toward improved functional immunogenicity of C3-GT compared to postfusion gB. Collectively, these studies define engineering principles to stabilize class III fusion proteins, provide reagents to interrogate the human antibody response to EBV gB, and lay a foundation for further studies to develop EBV gB-based vaccine candidates.
- 3 January 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Top Cited PapersOpen AccessStructure and immunogenicity of an engineered soluble prefusion-stabilized EBV gB antigen
Epstein-Barr virus (EBV), the causative agent of mononucleosis, is linked to over 140,000 annual cancer-related deaths globally and increases the risk of multiple sclerosis by up to 32-fold. As a herpesvirus, EBV establishes lifelong infection, and over 90% of U.S. adults are EBV-seropositive. Despite its significant disease burden, no approved EBV vaccines or therapeutics exist. Among EBV envelope glycoproteins, the fusion protein (gB) is strictly required for epithelial and B cell infection. Here, using a combination of AlphaFold-guided modeling, rational design, and ThermoMPNN-informed optimization, we engineer a stabilized prefusion gB variant, C3-GT. This construct incorporates two inter-protomeric disulfide bonds and three cavity-filling substitutions, resulting in a melting temperature of 54 °C. Cryo-EM analysis of this construct reveals the prefusion structure of EBV gB, providing insights into the structural transitions required to adopt the postfusion conformation. Murine immunizations and depletion studies with human sera suggest a trend toward improved functional immunogenicity of C3-GT compared to postfusion gB. Collectively, these studies define engineering principles to stabilize class III fusion proteins, provide reagents to interrogate the human antibody response to EBV gB, and lay a foundation for further studies to develop EBV gB-based vaccine candidates.
- Open Access
Design, Structure, and Immunogenicity of a Soluble Prefusion-stabilized EBV gB Antigen
Epstein-Barr virus (EBV), the causative agent of mononucleosis, is linked to over 140,000 annual cancer-related deaths globally and increases the risk of multiple sclerosis by up to 32-fold. As a herpesvirus, EBV establishes lifelong infection, and over 90% of U.S. adults are EBV-seropositive. Despite its significant disease burden, no approved EBV vaccines or therapeutics exist. Among EBV envelope glycoproteins, the fusion protein (gB) is strictly required for epithelial and B cell infection. Using a combination of AlphaFold-guided modeling, rational design, and ThermoMPNN-informed optimization, we engineered a stabilized prefusion gB variant, D2C3. This construct incorporates two inter-protomeric disulfide bonds and three cavity-filling substitutions, resulting in a melting temperature of 54 °C. Cryo-EM analysis of this construct allowed us to determine the prefusion structure of EBV gB, providing insights into the structural transitions required to adopt the postfusion conformation. Murine immunizations and depletion studies with human sera suggested a trend toward improved functional immunogenicity of D2C3 compared to postfusion gB. Collectively, these studies define engineering principles to stabilize class III fusion proteins, provide reagents to interrogate the human antibody response to EBV gB, and lay a foundation for further studies to develop EBV gB-based vaccine candidates.
Open AccessDesign, Structure, and Immunogenicity of a Soluble Prefusion-stabilized EBV gB Antigen
Epstein-Barr virus (EBV), the causative agent of mononucleosis, is linked to over 140,000 annual cancer-related deaths globally and increases the risk of multiple sclerosis by up to 32-fold. As a herpesvirus, EBV establishes lifelong infection, and over 90% of U.S. adults are EBV-seropositive. Despite its significant disease burden, no approved EBV vaccines or therapeutics exist. Among EBV envelope glycoproteins, the fusion protein (gB) is strictly required for epithelial and B cell infection. Using a combination of AlphaFold-guided modeling, rational design, and ThermoMPNN-informed optimization, we engineered a stabilized prefusion gB variant, D2C3. This construct incorporates two inter-protomeric disulfide bonds and three cavity-filling substitutions, resulting in a melting temperature of 54 °C. Cryo-EM analysis of this construct allowed us to determine the prefusion structure of EBV gB, providing insights into the structural transitions required to adopt the postfusion conformation. Murine immunizations and depletion studies with human sera suggested a trend toward improved functional immunogenicity of D2C3 compared to postfusion gB. Collectively, these studies define engineering principles to stabilize class III fusion proteins, provide reagents to interrogate the human antibody response to EBV gB, and lay a foundation for further studies to develop EBV gB-based vaccine candidates.
- Open Access
A stabilized MERS-CoV spike ferritin nanoparticle vaccine elicits robust and protective neutralizing antibody responses
Summary: Middle East respiratory syndrome coronavirus (MERS-CoV) was first identified as a human pathogen in 2012 and causes ongoing sporadic infections and outbreak clusters. Despite case fatality rates (CFRs) of over 30% and the pandemic potential associated with betacoronaviruses, a safe and efficacious vaccine has not been developed for prevention of MERS in at-risk individuals. Here we report the design, in vitro characterization, and preclinical evaluation of MERS-CoV antigens. Our lead candidate comprises a stabilized spike ectodomain displayed on a self-assembling ferritin nanoparticle that can be produced from a high-expressing, stable cell pool. This vaccine elicits robust antibody titers in BALB/c mice as measured by MERS- CoV pseudovirus and live-virus neutralization assays. Immunization of non-human primates (NHPs) with a single dose of Alhydrogel-adjuvanted vaccine elicits >10 3 geometric mean titer (GMT) of pseudovirus neutralizing antibodies that can be boosted with a second dose. These antibody levels are durable, with GMTs that surpass the post-prime levels for more than 5 months post-boost. Importantly, sera from these NHPs exhibit broad cross-reactivity against lentiviruses pseudotyped with spike proteins from MERS-CoV clades A, B, and C as well as a more distant pangolin merbecovirus. In transgenic mice expressing human DPP4, immunization provided dose-dependent protection against MERS-CoV lethal challenge, and in an established alpaca challenge model, immunization fully protected against MERS-CoV infection. This protein-based MERS-CoV nanoparticle vaccine is a promising candidate for advancement to clinical development to protect at-risk individuals and for future use in a potential outbreak setting.
Open AccessA stabilized MERS-CoV spike ferritin nanoparticle vaccine elicits robust and protective neutralizing antibody responses
Summary: Middle East respiratory syndrome coronavirus (MERS-CoV) was first identified as a human pathogen in 2012 and causes ongoing sporadic infections and outbreak clusters. Despite case fatality rates (CFRs) of over 30% and the pandemic potential associated with betacoronaviruses, a safe and efficacious vaccine has not been developed for prevention of MERS in at-risk individuals. Here we report the design, in vitro characterization, and preclinical evaluation of MERS-CoV antigens. Our lead candidate comprises a stabilized spike ectodomain displayed on a self-assembling ferritin nanoparticle that can be produced from a high-expressing, stable cell pool. This vaccine elicits robust antibody titers in BALB/c mice as measured by MERS- CoV pseudovirus and live-virus neutralization assays. Immunization of non-human primates (NHPs) with a single dose of Alhydrogel-adjuvanted vaccine elicits >10 3 geometric mean titer (GMT) of pseudovirus neutralizing antibodies that can be boosted with a second dose. These antibody levels are durable, with GMTs that surpass the post-prime levels for more than 5 months post-boost. Importantly, sera from these NHPs exhibit broad cross-reactivity against lentiviruses pseudotyped with spike proteins from MERS-CoV clades A, B, and C as well as a more distant pangolin merbecovirus. In transgenic mice expressing human DPP4, immunization provided dose-dependent protection against MERS-CoV lethal challenge, and in an established alpaca challenge model, immunization fully protected against MERS-CoV infection. This protein-based MERS-CoV nanoparticle vaccine is a promising candidate for advancement to clinical development to protect at-risk individuals and for future use in a potential outbreak setting.
- Open Access
- 30 June 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 8 (84) , eadd7446
Rapid recruitment and IFN-I–mediated activation of monocytes dictate focal radiotherapy efficacy
The recruitment of monocytes and their differentiation into immunosuppressive cells is associated with the low efficacy of preclinical nonconformal radiotherapy (RT) for tumors. However, nonconformal RT (non-CRT) does not mimic clinical practice, and little is known about the role of monocytes after RT modes used in patients, such as conformal RT (CRT). Here, we investigated the acute immune response induced by after CRT. Contrary to non-CRT approaches, we found that CRT induces a rapid and robust recruitment of monocytes to the tumor that minimally differentiate into tumor-associated macrophages or dendritic cells but instead up-regulate major histocompatibility complex II and costimulatory molecules. We found that these large numbers of infiltrating monocytes are responsible for activating effector polyfunctional CD8 + tumor-infiltrating lymphocytes that reduce tumor burden. Mechanistically, we show that monocyte-derived type I interferon is pivotal in promoting monocyte accumulation and immunostimulatory function in a positive feedback loop. We also demonstrate that monocyte accumulation in the tumor microenvironment is hindered when RT inadvertently affects healthy tissues, as occurs in non-CRT. Our results unravel the immunostimulatory function of monocytes during clinically relevant modes of RT and demonstrate that limiting the exposure of healthy tissues to radiation has a positive therapeutic effect on the overall antitumor immune response.
- 30 June 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 8 (84) , eadd7446
Open AccessRapid recruitment and IFN-I–mediated activation of monocytes dictate focal radiotherapy efficacy
The recruitment of monocytes and their differentiation into immunosuppressive cells is associated with the low efficacy of preclinical nonconformal radiotherapy (RT) for tumors. However, nonconformal RT (non-CRT) does not mimic clinical practice, and little is known about the role of monocytes after RT modes used in patients, such as conformal RT (CRT). Here, we investigated the acute immune response induced by after CRT. Contrary to non-CRT approaches, we found that CRT induces a rapid and robust recruitment of monocytes to the tumor that minimally differentiate into tumor-associated macrophages or dendritic cells but instead up-regulate major histocompatibility complex II and costimulatory molecules. We found that these large numbers of infiltrating monocytes are responsible for activating effector polyfunctional CD8 + tumor-infiltrating lymphocytes that reduce tumor burden. Mechanistically, we show that monocyte-derived type I interferon is pivotal in promoting monocyte accumulation and immunostimulatory function in a positive feedback loop. We also demonstrate that monocyte accumulation in the tumor microenvironment is hindered when RT inadvertently affects healthy tissues, as occurs in non-CRT. Our results unravel the immunostimulatory function of monocytes during clinically relevant modes of RT and demonstrate that limiting the exposure of healthy tissues to radiation has a positive therapeutic effect on the overall antitumor immune response.
- Open Access
- 5 October 2022
- Published by Elsevier in Journal of Ginseng Research
- Vol. 47 (2) , 302-310
Proteomic analysis for the effects of non-saponin fraction with rich polysaccharide from Korean Red Ginseng on Alzheimer's disease in a mouse model
- 5 October 2022
- Published by Elsevier in Journal of Ginseng Research
- Vol. 47 (2) , 302-310
Open AccessProteomic analysis for the effects of non-saponin fraction with rich polysaccharide from Korean Red Ginseng on Alzheimer's disease in a mouse model